FY18 revenues: uninspiring
FY18 revenues: uninspiringEARNINGS/SALES RELEASES
FACT
DMS released FY18 sales which reached €24.3m (-10%), including a 12% fall in the historic Imaging business to €23.3m (95% of total revenues) and an increase in Wellness and Biotech (from €0.5m to €1m).
ANALYSIS
The same story as previous quarters: new segments are growing (from scratch) while the historic Imaging business was still down, but at a slower pace (around 5% according to us). As a result, revenues in FY18 landed significantly under our estimate (€28.3m) and remain disappointing given the group’s previous comments. Note that the long-promised Egyptian order (after the group won a tender in early FY18) has still not been billed. The group indicates that French sales were up 20% in Imaging in FY18, which implies rather weak international sales. As far as new segments are concerned, the situation has not changed much: DMS Biotech sales were up 26% (again from a low basis), with a ramp-up in the number of countries where Adip’Sculpt devices are sold (23 currently). DMS Wellness booked sales of €0.3m, quite a small number, with management expecting an uptake in revenues in FY19.
The due-diligence process with a view to contributing the Imaging business to a new entity (see our comment dated 7 February 2019) is still ongoing, with no guarantee that the deal will go through, even if we are still not quite convinced by this mysterious move. We will of course reconsider this opinion once (and if) the deal succeeds, with DMS giving some more insight on their intentions.
IMPACT
We will revisit our numbers and model when the group releases FY18 results (together with Q119 sales) on 29 April.
DIAGNOSTIC MEDICAL SYSTEMS SA, (formerly known as DMS), is a France-based company, which together with its subsidiaries, designs, produces and markets medical imagery devices dedicated to conventional and digital radiology as well as bone densitometry. The Company manufactures a range of products for bone densitometry examination, including the ultrasound imaging system UBIS 5000, Challenger Envision, Stratos dR and Stratos. In the radiology sector, its products include Baccara dRF 43, EOL, Platinum and Da Vinci solutions, among others. In addition, it offers such products as scanners, transcranial Doppler, and Giotto Image mammography system. The Company operates several direct subsidiaries, AXS Medical, Apelem SAS, which manufactures radiology equipment, Medilink SARL, which produces Doppler and bone densitometry devices, Apelem SA, based in Spain, Alpha MOS based in France and one indirect subsidiary, SA Apelem and one indirect affiliated company, Spectrap.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.